Chicago Capital Management LLC acquired a new stake in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the medical instruments supplier’s stock, valued at approximately $31,611,000. C.R. Bard comprises 7.0% of Chicago Capital Management LLC’s portfolio, making the stock its 2nd largest position. Chicago Capital Management LLC owned 0.14% of C.R. Bard as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. UBS Asset Management Americas Inc. increased its position in shares of C.R. Bard by 3.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 267,451 shares of the medical instruments supplier’s stock valued at $60,087,000 after buying an additional 9,134 shares during the period. Perigon Wealth Management LLC increased its position in C.R. Bard by 14.6% in the fourth quarter. Perigon Wealth Management LLC now owns 2,566 shares of the medical instruments supplier’s stock valued at $631,000 after buying an additional 327 shares during the last quarter. Teachers Advisors LLC increased its position in C.R. Bard by 3.5% in the fourth quarter. Teachers Advisors LLC now owns 134,481 shares of the medical instruments supplier’s stock valued at $30,213,000 after buying an additional 4,500 shares during the last quarter. Kentucky Retirement Systems bought a new position in C.R. Bard during the fourth quarter valued at about $1,199,000. Finally, Kentucky Retirement Systems Insurance Trust Fund bought a new position in C.R. Bard during the fourth quarter valued at about $535,000. 85.32% of the stock is owned by institutional investors and hedge funds.
Shares of C.R. Bard, Inc. (BCR) traded up 0.19% during mid-day trading on Friday, reaching $319.75. 330,226 shares of the company’s stock were exchanged. The company has a market cap of $23.24 billion, a PE ratio of 41.98 and a beta of 0.59. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $323.27. The company’s 50-day moving average price is $319.00 and its 200 day moving average price is $283.44.
C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the previous year, the company posted $2.54 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s payout ratio is 13.67%.
WARNING: “Chicago Capital Management LLC Buys Shares of 100,000 C.R. Bard, Inc. (NYSE:BCR)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/12/chicago-capital-management-llc-acquires-shares-of-100000-c-r-bard-inc-nysebcr-updated-updated-updated.html.
Several analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price on the stock in a research report on Tuesday, June 13th. BMO Capital Markets lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target on the stock. in a research report on Tuesday, April 25th. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. BidaskClub lowered shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $285.67.
In other news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.80% of the company’s stock.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.